Illumina launches BioInsight Platform to speed genomic data analysis with AI and unified software.

Illumina introduced the BioInsight Platform, a unified software environment that integrates advanced AI, curated biological data, and Illumina's analysis tools to help researchers quickly turn complex genomic and multiomic data into actionable insights. The platform includes the updated DRAGEN v4.6 software, which offers flexible deployment across cloud and standard computing environments, enhancing large-scale genomic research like Parkinson's disease studies. By simplifying access to data, AI models, and software in one place, BioInsight aims to accelerate biological discovery and support precision medicine advancements. Illumina plans ongoing updates to expand platform capabilities for researchers and biopharma partners.

Illumina shares trade at USD 270.68 on Pluang as of Oct 14, 2026, 20:11 WIB, down 0.18% for the day. The stock holds a market cap of $40.95 billion and a 52-week high of $293.69. Pluang investors show full buying interest with 100% buy orders and an average hold time of 83 days.